{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:03:10Z","timestamp":1773745390699,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Opioids are not recommended for fibromyalgia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the frequency of opioid use in a large cohort of fibromyalgia patients and to identify factors associated with opioid consumption.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective, observational study of a large fibromyalgia cohort in a tertiary care center. We assessed fibromyalgia severity, functional capacity, anxiety, depression, drugs consumption and the patient\u2019s impression of change. We compared strong opioid consumers (SOC) and non-SOC. Inferential statistical and logistic regression analysis were used to identify factors associated with opioid consumption, and ANOVA for repeated measurements.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found a prevalence of 9.2% of SOC (100 patients) among 1087 patients in the cohort. During the last four years there was a significant increase on the incidence of SOC up to 12.8% (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). There were no differences in demographic variables between SOC and non-SOC. Clinical variables were significantly more severe in SOC, and they consumed more non-opioid drugs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Opioid consumption was independently associated with other non-opioid drugs (Odds ratio 1.25, CI: 1.13\u20131.38), but not with the fibromyalgia severity. At three months, 62% of the patients had opioid withdrawal. There were no statistical differences in the fibromyalgia severity at the initial evaluation, or the patient\u2019s impression of change compared with those patients who continued opioids. Coping strategies were better in those patients who withdrew opioids (<jats:italic>p<\/jats:italic>\u2009=\u20090.044).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We observed an increase in opioid prescriptions during the last four years. Opioid consumption was associated with concomitant use of non-opioid drugs, but it was not associated with fibromyalgia severity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-024-07263-x","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T11:02:20Z","timestamp":1707476540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Opioids and fibromyalgia: frequency of use and factors associated with increased consumption in patients remitted to a tertiary care center"],"prefix":"10.1186","volume":"25","author":[{"given":"Javier","family":"Rivera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Molina-Collada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Mart\u00ednez-Barrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Serrano-Benavente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Castrej\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Mar\u00eda","family":"\u00c1lvaro-Gracia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"issue":"3","key":"7263_CR1","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1097\/PR9.0000000000000599","volume":"2","author":"W H\u00e4user","year":"2017","unstructured":"H\u00e4user W, Schug S, Furlan AD. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. PAIN Rep. 2017;2(3):e599.","journal-title":"PAIN Rep"},{"issue":"4","key":"7263_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1056\/NEJMsr1706626","volume":"377","author":"ND Volkow","year":"2017","unstructured":"Volkow ND, Collins FS. The role of Science in addressing the Opioid Crisis. N Engl J Med. 2017;377(4):392\u20134.","journal-title":"N Engl J Med"},{"issue":"12","key":"7263_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.medcli.2018.04.011","volume":"151","author":"D Fuster","year":"2018","unstructured":"Fuster D, Muga R. La crisis de Los opioides. Medicina Cl\u00ednica. 2018;151(12):487\u20138.","journal-title":"Medicina Cl\u00ednica"},{"key":"7263_CR4","unstructured":"Agencia Espa\u00f1ola de Medicamentos y productos Sanitarios. Utilizaci\u00f3n de medicamentos opioides en Espa\u00f1a durante el periodo 2008\u20132015. 2017. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/observatorio\/docs\/opioides-2008-2015.pdf."},{"issue":"4","key":"7263_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.7326\/M14-2559","volume":"162","author":"R Chou","year":"2015","unstructured":"Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of Long-Term Opioid Therapy for Chronic Pain: a Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276\u201386.","journal-title":"Ann Intern Med"},{"key":"7263_CR6","doi-asserted-by":"publisher","first-page":"564412","DOI":"10.3389\/fphar.2020.564412","volume":"11","author":"H De Sola","year":"2020","unstructured":"De Sola H, Due\u00f1as M, Salazar A, Ortega-Jim\u00e9nez P, Failde I. Prevalence of therapeutic use of Opioids in Chronic Non-cancer Pain patients and Associated factors: a systematic review and Meta-analysis. Front Pharmacol. 2020;11:564412.","journal-title":"Front Pharmacol"},{"issue":"2","key":"7263_CR7","doi-asserted-by":"publisher","first-page":"e001029","DOI":"10.1136\/rmdopen-2019-001029","volume":"5","author":"AP Trouvin","year":"2019","unstructured":"Trouvin AP, Berenbaum F, Perrot S. The opioid epidemic: helping rheumatologists prevent a crisis. RMD Open. 2019;5(2):e001029.","journal-title":"RMD Open"},{"issue":"9","key":"7263_CR8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.1780400904","volume":"40","author":"F Wolfe","year":"1997","unstructured":"Wolfe F. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40(9):1560\u201370.","journal-title":"Arthritis Rheum"},{"issue":"37","key":"7263_CR9","doi-asserted-by":"publisher","first-page":"10000","DOI":"10.1523\/JNEUROSCI.2849-07.2007","volume":"27","author":"RE Harris","year":"2007","unstructured":"Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central -opioid receptor availability in Fibromyalgia. J Neurosci. 2007;27(37):10000\u20136.","journal-title":"J Neurosci"},{"key":"7263_CR10","doi-asserted-by":"crossref","unstructured":"Watkins L, Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci. 2005;28(12):661-9. Trends Neurosci. 2005;28(12):661\u20139.","DOI":"10.1016\/j.tins.2005.10.001"},{"key":"7263_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.bbi.2018.09.018","volume":"75","author":"DS Albrecht","year":"2019","unstructured":"Albrecht DS, Forsberg A, Sandstr\u00f6m A, Bergan C, Kadetoff D, Protsenko E, et al. Brain glial activation in fibromyalgia \u2013 a multi-site positron emission tomography investigation. Brain Behav Immun. 2019;75:72\u201383.","journal-title":"Brain Behav Immun"},{"issue":"4","key":"7263_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/ard.2007.071522","volume":"67","author":"SF Carville","year":"2008","unstructured":"Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67(4):536\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7263_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00482-012-1169-x","volume":"26","author":"W Eich","year":"2012","unstructured":"Eich W, H\u00e4user W, Arnold B, J\u00e4ckel W, Offenb\u00e4cher M, Petzke F, et al. Das Fibromyalgiesyndrom: definition, Klassifikation, Klinische diagnose und prognose. Schmerz. 2012;26(3):247\u201358.","journal-title":"Schmerz"},{"issue":"2","key":"7263_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","volume":"76","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, H\u00e4user W, Flu\u00df E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318\u201328.","journal-title":"Ann Rheum Dis"},{"key":"7263_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.reuma.2021.02.004","volume":"18","author":"J Rivera Redondo","year":"2022","unstructured":"Rivera Redondo J, D\u00edaz Del Campo Fontecha P, Alegre de Miquel C, Almirall Bernab\u00e9 M, Casanueva Fern\u00e1ndez B, Castillo Ojeda C, et al. Recommendations by the Spanish Society of Rheumatology on Fibromyalgia. Part 1: Diagnosis and treatment. Reumatol Clin (Engl Ed). 2022 Mar;18(3):131\u201340.","journal-title":"Reumatol Clin"},{"issue":"2","key":"7263_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4081\/reumatismo.2021.1362","volume":"73","author":"A Ariani","year":"2021","unstructured":"Ariani A, Bazzichi L, Sarzi-Puttini P, Salaffi F, Manara M, Prevete I, et al. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of fibromyalgia. Best practices based on current scientific evidence. Reumatismo. 2021;73(2):89\u2013105.","journal-title":"Reumatismo"},{"issue":"1","key":"7263_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1477-7525-9-39","volume":"9","author":"MA Vallejo","year":"2011","unstructured":"Vallejo MA, Rivera J, Esteve-Vives J, Rejas J, Group ICAF. A confirmatory study of the Combined Index of Severity of Fibromyalgia (ICAF*): factorial structure, reliability and sensitivity to change. Health Qual Life Outcomes. 2011;9(1):39.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"7263_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Res. 2010;62(5):600\u201310.","journal-title":"Arthritis Care Res"},{"key":"7263_CR19","doi-asserted-by":"crossref","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington DC. USA: Goverment Printing Office; 1976. Available from: https:\/\/openlibrary.org\/books\/OL24341821M\/ECDEU_assessment_manual_for_psychopharmacology.","DOI":"10.1037\/e591322011-001"},{"issue":"1","key":"7263_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-7525-8-2","volume":"8","author":"MA Vallejo","year":"2010","unstructured":"Vallejo MA, Rivera J, Esteve-Vives J, Group ICAF. Development of a self-reporting tool to obtain a combined index of severity of Fibromyalgia (ICAF*). Health Qual Life Outcomes. 2010;8(1):2.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"7263_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3899\/jrheum.100594","volume":"38","author":"F Wolfe","year":"2011","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, H\u00e4user W, Katz RS, et al. Fibromyalgia Criteria and Severity scales for Clinical and Epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113\u201322.","journal-title":"J Rheumatol"},{"issue":"e000146","key":"7263_CR22","first-page":"1","volume":"1","author":"E Rampakakis","year":"2015","unstructured":"Rampakakis E, Ste-Marie PA, Sampalis JS, Karellis A, Shir Y, Fitzcharles MA. Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open. 2015;1(e000146):1.","journal-title":"RMD Open"},{"issue":"3","key":"7263_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clinthera.2013.02.003","volume":"35","author":"JT Painter","year":"2013","unstructured":"Painter JT, Crofford LJ, Talbert J. Geographic Variation of Chronic Opioid Use in Fibromyalgia. Clin Ther. 2013;35(3):303\u201311.","journal-title":"Clin Ther"},{"issue":"10","key":"7263_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.amjmed.2011.05.031","volume":"124","author":"MA Fitzcharles","year":"2011","unstructured":"Fitzcharles MA, Ste-Marie PA, Gamsa A, Ware MA, Shir Y. Opioid Use, Misuse, and abuse in patients labeled as Fibromyalgia. Am J Med. 2011;124(10):955\u201360.","journal-title":"Am J Med"},{"issue":"3","key":"7263_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11926-012-0311-1","volume":"15","author":"D Krashin","year":"2013","unstructured":"Krashin D. What are we treating with chronic opioid therapy? Curr Rheumatol Rep. 2013;15(3):311.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"7263_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2474-8-27","volume":"8","author":"RM Bennett","year":"2007","unstructured":"Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8(1):27.","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"7263_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/RHU.0000000000001273","volume":"27","author":"BK Bruce","year":"2021","unstructured":"Bruce BK, Allman ME, Rivera FA, Abril A, Gehin JM, Oliphant LM, et al. Opioid use in Fibromyalgia continues despite guidelines that do not support its efficacy or risk. J Clin Rheumatol. 2021;27(5):187\u201393.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"7263_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/AJP.0000000000000079","volume":"31","author":"X Peng","year":"2015","unstructured":"Peng X, Robinson RL, Mease P, Kroenke K, Williams DA, Chen Y, et al. Long-term evaluation of Opioid Treatment in Fibromyalgia. Clin J Pain. 2015;31(1):7\u201313.","journal-title":"Clin J Pain"},{"issue":"7","key":"7263_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0002-9343(03)00116-5","volume":"114","author":"R Bennett","year":"2003","unstructured":"Bennett R. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114(7):537\u201345.","journal-title":"Am J Med"},{"issue":"1","key":"7263_CR30","first-page":"13","volume":"18","author":"G Biasi","year":"1998","unstructured":"Biasi G. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res. 1998;18(1):13\u20139.","journal-title":"Int J Clin Pharmacol Res"},{"key":"7263_CR31","doi-asserted-by":"crossref","unstructured":"Wasserman RA, Brummett CM, Goesling J, Tsodikov A, Hassett AL. Characteristics of Chronic Pain patients who take opioids and persistently Report High Pain Intensity: Regional Anesthesia and Pain Medicine. 2014;39(1):13\u20137.","DOI":"10.1097\/AAP.0000000000000024"},{"issue":"1","key":"7263_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1756-185X.2010.01567.x","volume":"14","author":"GS Ngian","year":"2011","unstructured":"Ngian GS, Guymer EK, Littlejohn GO. The use of opioids in fibromyalgia: use of opioids in fibromyalgia. Int J Rheum Dis. 2011;14(1):6\u201311.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"7263_CR33","doi-asserted-by":"publisher","first-page":"e13913","DOI":"10.1097\/MD.0000000000013913","volume":"98","author":"Jmoon Hwang","year":"2019","unstructured":"Hwang Jmoon, Lee B, joo, Oh TH, Park D, Kim Chyun. Association between initial opioid use and response to a brief interdisciplinary treatment program in fibromyalgia. Medicine. 2019;98(1):e13913.","journal-title":"Medicine"},{"issue":"6","key":"7263_CR34","doi-asserted-by":"publisher","first-page":"e13020","DOI":"10.1111\/jsr.13020","volume":"29","author":"CS McCrae","year":"2020","unstructured":"McCrae CS, Curtis AF, Miller MB, Nair N, Rathinakumar H, Davenport M, et al. Effect of cognitive behavioural therapy on sleep and opioid medication use in adults with fibromyalgia and insomnia. J Sleep Res. 2020;29(6):e13020.","journal-title":"J Sleep Res"},{"issue":"9","key":"7263_CR35","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/pm\/pnv079","volume":"17","author":"JL Cunningham","year":"2016","unstructured":"Cunningham JL, Evans MM, King SM, Gehin JM, Loukianova LL. Opioid tapering in Fibromyalgia patients: experience from an Interdisciplinary Pain Rehabilitation Program. Pain Med. 2016;17(9):1676\u201385.","journal-title":"Pain Med"},{"issue":"11","key":"7263_CR36","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/pm\/pny231","volume":"20","author":"DA Fishbain","year":"2019","unstructured":"Fishbain DA, Pulikal A. Does Opioid Tapering in Chronic Pain patients result in Improved Pain or same Pain vs increased Pain at Taper Completion? A structured evidence-based systematic review. Pain Med. 2019;20(11):2179\u201397.","journal-title":"Pain Med"},{"issue":"1","key":"7263_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4637.2007.00253.x","volume":"8","author":"W Hooten","year":"2007","unstructured":"Hooten W. Treatment outcomes after multidisciplinary pain rehabilitation with analgesic medication withdrawal for patients with fibromyalgia. Pain Med. 2007;8(1):8\u201316.","journal-title":"Pain Med"},{"issue":"50\u201351","key":"7263_CR38","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","volume":"65","author":"R Rudd","year":"2016","unstructured":"Rudd R. Increases in drug and opioid-involved overdose deaths - United States, 2010\u20132015. MMWR Morb Mortal Wkly Rep. 2016;65(50\u201351):1445\u201352.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"7263_CR39","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/rheumatology\/ker203","volume":"50","author":"E Calandre","year":"2011","unstructured":"Calandre E. Suicide attempts and risk of suicide in patients with fibromyalgia: a survey in Spanish patients. Rheumatology (Oxford). 2011;50(10):1889\u201393.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"7263_CR40","first-page":"1","volume":"23","author":"S Babalonis","year":"2015","unstructured":"Babalonis S, Walsh SL. Risks of co-prescribing opioids and benzodiazepines. Pain Clin Updates. 2015;23(6):1\u20137.","journal-title":"Pain Clin Updates"},{"issue":"6","key":"7263_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/MLR.0b013e31824ebd81","volume":"50","author":"G Pierce","year":"2012","unstructured":"Pierce G. Doctor and pharmacy shopping for controlled substances. Med Care. 2012;50(6):494\u2013500.","journal-title":"Med Care"},{"key":"7263_CR42","doi-asserted-by":"crossref","unstructured":"Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case\u2013control study. Tsai AC, editor. PLoS Med. 2017;14(10):e1002396.","DOI":"10.1371\/journal.pmed.1002396"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-024-07263-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-024-07263-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-024-07263-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T11:06:27Z","timestamp":1707476787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-024-07263-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7263"],"URL":"https:\/\/doi.org\/10.1186\/s12891-024-07263-x","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration of 1975, as revised in 2013. All data were anonymized, and the study was approved by the Ethics Committee of Hospital General Universitario Gregorio Mara\u00f1\u00f3n (08\/2021; April 6th, 2021), Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM). Madrid. Spain.Informed consent was obtained from all subjects before to the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}